0.9399
price down icon0.23%   -0.0022
after-market 시간 외 거래: .92 -0.0199 -2.12%
loading
전일 마감가:
$0.9421
열려 있는:
$0.92
하루 거래량:
208.68K
Relative Volume:
0.24
시가총액:
$60.85M
수익:
$8.38M
순이익/손실:
$-27.19M
주가수익비율:
-0.8623
EPS:
-1.09
순현금흐름:
$-13.59M
1주 성능:
+1.78%
1개월 성능:
-5.49%
6개월 성능:
-21.02%
1년 성능:
+0.00%
1일 변동 폭
Value
$0.9011
$0.9974
1주일 범위
Value
$0.9011
$1.05
52주 변동 폭
Value
$0.65
$1.75

Opus Genetics Inc Stock (IRD) Company Profile

Name
명칭
Opus Genetics Inc
Name
전화
248-681-9815
Name
주소
8 DAVIS DRIVE, DURHAM
Name
직원
18
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
IRD's Discussions on Twitter

IRD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IRD
Opus Genetics Inc
0.9399 60.85M 8.38M -27.19M -13.59M -1.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Opus Genetics Inc Stock (IRD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-11 개시 Craig Hallum Buy
2024-11-13 재개 H.C. Wainwright Buy

Opus Genetics Inc 주식(IRD)의 최신 뉴스

pulisher
Jun 17, 2025

Opus Genetics (IRD) Receives "Buy" Rating from Lucid Capital Markets | IRD Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Opus Genetics (IRD) Receives "Buy" Rating from Lucid Capital Mar - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Opus Genetics (IRD) Receives Buy Rating Amid Promising Trial Res - GuruFocus

Jun 17, 2025
pulisher
Jun 02, 2025

Opus Genetics, Inc.Common Stock (Nasdaq:IRD) Stock Quote - FinancialContent

Jun 02, 2025
pulisher
Jun 02, 2025

Opus Genetics (IRD) Achieves Success in Phase 3 Trial for Night Driving Vision Treatment | IRD Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Opus Genetics reports success in night vision trial - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Opus Genetics reports success in night vision trial By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its - GlobeNewswire

Jun 02, 2025
pulisher
Jun 02, 2025

Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewswire Inc.

Jun 02, 2025
pulisher
May 19, 2025

Analysts Are Upgrading Opus Genetics, Inc. (NASDAQ:IRD) After Its Latest Results - simplywall.st

May 19, 2025
pulisher
May 18, 2025

Opus Genetics, Inc. (NASDAQ:IRD) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance

May 18, 2025
pulisher
May 16, 2025

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 16, 2025
pulisher
May 16, 2025

Opus Genetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025
pulisher
May 15, 2025

Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewswire

May 15, 2025
pulisher
May 15, 2025

IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Opus Genetics Inc (IRD) Q1 2025 Earnings: EPS of $(0.24) Beats E - GuruFocus

May 15, 2025
pulisher
May 15, 2025

IRD Reports Strong Q1 Revenue Growth and Encouraging Trial Data | IRD Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Opus Genetics Q1 2025 Financial Results and Corporate Update - TradingView

May 15, 2025
pulisher
May 15, 2025

Opus Gene Therapy Shows 12-Month Vision Restoration Success, Gains FDA RMAT Status | IRD Stock News - Stock Titan

May 15, 2025
pulisher
May 12, 2025

Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Co - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Opus Genetics (IRD) Showcases Advances in Gene Therapy at May Conferences | IRD Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Opus Genetics to Present Advances in Gene Therapy for Inherited Retinal Diseases at Major Scientific Conferences in May 2025 - Nasdaq

May 12, 2025
pulisher
May 12, 2025

Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May - GlobeNewswire

May 12, 2025
pulisher
May 07, 2025

FDA grants RMAT status to Opus Genetics’ OPGx-LCA5 gene therapy - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LC - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Opus Genetics (IRD) Secures RMAT Status for Gene Therapy OPGx-LCA5 | IRD Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

FDA grants Opus Genetics RMAT status for eye therapy - Investing.com

May 06, 2025
pulisher
May 06, 2025

Opus Genetics Granted FDA Regenerative Medicine Advanced - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate - The Manila Times

May 06, 2025
pulisher
May 06, 2025

FDA grants Opus Genetics RMAT status for eye therapy By Investing.com - Investing.com South Africa

May 06, 2025
pulisher
May 06, 2025

FDA Fast-Tracks Revolutionary Gene Therapy for Ultra-Rare Inherited Blindness Treatment - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Opus Genetics (IRD) Reveals Promising Gene Therapy Trial Results | IRD Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision - The Manila Times

May 05, 2025
pulisher
May 05, 2025

Opus Genetics Announces Presentation of OPGX-LCA5 Gene - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Gene Therapy Breakthrough: Opus Reports 3.5-Line Vision Improvement After 1 Year in Rare Eye Disease Trial - Stock Titan

May 05, 2025
pulisher
May 04, 2025

IRDOpus Genetics Latest Stock News & Market Updates - Stock Titan

May 04, 2025
pulisher
May 02, 2025

Earnings Preview: Opus Genetics, Inc. (IRD) Q1 Earnings Expected to Decline - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Opus Genetics shareholders approve key proposals By Investing.com - Investing.com Nigeria

May 01, 2025
pulisher
May 01, 2025

Opus Genetics shareholders approve key proposals - Investing.com

May 01, 2025
pulisher
Apr 28, 2025

Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 - marketscreener.com

Apr 28, 2025
pulisher
Apr 15, 2025

PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath - markets.businessinsider.com

Apr 15, 2025

Opus Genetics Inc (IRD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Opus Genetics Inc 주식 (IRD) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
YERXA BENJAMIN R
President
Nov 21 '24
Buy
0.98
10,000
9,834
342,800
Magrath George
Chief Executive Officer
Nov 15 '24
Buy
1.01
90,294
91,215
483,244
Magrath George
Chief Executive Officer
Nov 18 '24
Buy
1.02
9,706
9,943
492,950
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
자본화:     |  볼륨(24시간):